RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
29.73
-0.69 (-2.25%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close30.42
Open29.78
Bid0.00 x 0
Ask0.00 x 0
Day's Range29.53 - 29.79
52 Week Range25.25 - 36.82
Volume1,657,148
Avg. Volume1,276,380
Market Cap204.16B
Beta0.53
PE Ratio (TTM)20.32
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.03 (3.38%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Starbucks' Schultz and Chandrasekaran on the 'Upstanders' series
    Yahoo Finance Video11 days ago

    Starbucks' Schultz and Chandrasekaran on the 'Upstanders' series

    Yahoo Finance's Julia La Roche speaks with Starbucks' Howard Schultz and Rajiv Chandrasekaran about season 2 of 'Upstanders.'

  • Roche (RHHBY) Reports Sales Numbers for First 9 Months
    Zacks15 hours ago

    Roche (RHHBY) Reports Sales Numbers for First 9 Months

    Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.

  • BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
    Zacks17 hours ago

    BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer

    BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.

  • Reuters2 days ago

    Roche Q3 sales beat forecasts as Ocrevus shines

    Roche's third-quarter sales rose 6 percent, the world's biggest cancer drug maker said on Thursday, beating analyst forecasts thanks to better-than-expected revenue from its new multiple sclerosis medicine ...

  • The Wall Street Journal2 days ago

    [$$] Roche Sales Boosted by New Drugs

    Roche said that third-quarter sales increased 4.9%, boosted by its pipeline of recently launched drugs.

  • Roche's Top Drug Stumbles in Europe as Biosimilars Take Hold
    Bloomberg2 days ago

    Roche's Top Drug Stumbles in Europe as Biosimilars Take Hold

    Roche Holding AG’s top-selling drug Rituxan saw sales slide in Europe last quarter, hurt by competition from cheaper copycat medicines called biosimilars -- a harbinger of things to come for the aging ...

  • Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
    Zacks3 days ago

    Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

    At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

  • ImmunoGen to Push Leukemia Candidate into Phase I Trial
    Zacks4 days ago

    ImmunoGen to Push Leukemia Candidate into Phase I Trial

    ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.

  • Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
    Zacks4 days ago

    Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

    Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

  • Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
    Zacks5 days ago

    Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion

    Foreign markets remain undeterred by discouraging events, notching up weekly gains.

  • Forbes9 days ago

    Roche's Blockbuster Oncology Drugs Losing Steam As They Approach Patent Expiry

    Roche Holdings’ oncology business accounts for over 50% of the company valuation, according to our estimates. The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016

  • Reuters9 days ago

    'Double whammy' for Roche as manufacturing patent losses loom

    Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. Roche's so-called "Cabilly patents" protect a pivotal step in manufacturing therapeutic antibodies, but end on Dec. 18, 2018. For decades, these patents allowed Roche to extract cash from dozens of drugmakers.

  • Reuters9 days ago

    'Double whammy' for Roche as manufacturing patent losses loom

    Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. Roche's so-called "Cabilly patents" protect a pivotal step in manufacturing therapeutic antibodies, but end on Dec. 18, 2018. For decades, these patents allowed Roche to extract cash from dozens of drugmakers.

  • Is This the Best Precision Medicine Stock to Buy?
    Motley Fool11 days ago

    Is This the Best Precision Medicine Stock to Buy?

    Foundation Medicine is on the cusp of a tidal shift in cancer treatment.

  • AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
    Zacks12 days ago

    AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation

    AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.

  • Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
    Zacks12 days ago

    Roche (RHHBY) Receives FDA Approval For Cobas Zika Test

    The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.

  • Reuters16 days ago

    Roche bladder cancer drug struggles as medics focus on survival

    Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer. Many modern cancer drugs are approved on the basis of alternative clinical endpoints, such as tumour shrinkage or reduced risk of disease progression, but extending patients' lives remains the most important benchmark for oncologists. Latest data show Tecentriq's share of the bladder cancer market has slipped to 32 percent from around 45 percent before May's surprise clinical trial failure, according to an analysis on Thursday by Barclays analysts.

  • Reuters17 days ago

    S.Africa watchdog drops over-charging probe into Aspen, Equity

    In June, the Competition Commission said it would investigate Aspen, U.S. company Pfizer, Swiss-based Roche Holding and its subsidiary Genentech, and Equity, a division of Clinigen South Africa, for suspected excessive pricing in the provision of specific cancer medicines in the country. "Based on the information gathered to date, the Commission has decided to drop the investigation against Aspen and Equity because an excessive pricing case cannot be sustained against them," the agency said in a statement on Wednesday.

  • Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
    Zacks18 days ago

    Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA

    Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.

  • FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
    Zacks18 days ago

    FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

    Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

  • Prothena's Psoriasis Candidate Disappoints in Phase I Study
    Zacks19 days ago

    Prothena's Psoriasis Candidate Disappoints in Phase I Study

    Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.

  • Reuters22 days ago

    Roche's Perjeta regimen gets FDA priority review in breast cancer

    The U.S. Food and Drug Administration has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche ...

  • Barrons.com24 days ago

    Pharmaceuticals: A Solid End To 2017

    Pharmaceutical stocks have had a pretty decent year, with the SPDR S&P Pharmaceuticals ETF(XPH) up 7.5%, although the performance of individual stocks was a bit mixed. Looking at head to the last quarter ...

  • Morningstar24 days ago

    Stock Market Outlook: China Rebalancing Presents Winners and Losers

    China's economic rebalancing means an overvalued basic materials sector, but consumption growth creates opportunities in areas such as telecom.

  • Market Realist25 days ago

    How Did Roche’s Diagnostics Division Perform in 1H17?

    In the first half of 2017, Roche’s (RHHBY) diagnostics division reported revenues of CHF 5.8 billion, which reflected a ~5.0% rise on a YoY (year-over-year) basis.